Pub Date : 2023-09-22eCollection Date: 2023-01-01DOI: 10.1177/11782218231195226
Orrin D Ware
The substance combination of codeine and promethazine, commonly termed lean/sizzurp, has been identified as a method that some individuals use to cope with PTSD and other mental health symptomology. A sample of 1423 adults with self-reported past year lean use was recruited from substance-related Reddit pages to complete a survey about lean, including information about using lean to cope with emotions, thoughts, or feelings. To be included in the sample, persons needed to: (1) be ⩾18 years old, (2) report past year lean use, (3) complete lean use screeners, and (4) pass data quality checks (eg, bot detection). As Reddit is an online forum, no geographic restrictions were placed on study participation. Data on demographic characteristics, lean use, and mental health disorder symptomology were captured from participants. Logistic regression models included anxiety, depression, and trauma as independent variables along with covariates to examine using lean to cope with emotions, thoughts, or feelings in the past 30 days. Most participants were male (n = 1102; 77.4%), with an average age of 26.9 (SD = 5.2) years. Most participants used included codeine as an ingredient in lean (n = 1060; 74.5%); promethazine was added as an ingredient by 31.7% of the sample (n = 451), and the combination of codeine and promethazine was included as ingredients by 13.5% (n = 192) of the sample. Participants with anxiety, lifetime trauma exposure, and who were female had increased odds of using lean to cope with emotions, thoughts, or feelings in the past 30 days. Those with depression and unstable housing exhibited decreased odds of using lean to cope with emotions, thoughts, or feelings in the past 30 days. This study recruited persons via social media to learn more about lean use, especially lean use to cope with mental health symptoms; future population-level studies are needed.
{"title":"Lean/Sizzurp Ingredients, Use, and Coping With Mental Health Symptoms.","authors":"Orrin D Ware","doi":"10.1177/11782218231195226","DOIUrl":"https://doi.org/10.1177/11782218231195226","url":null,"abstract":"<p><p>The substance combination of codeine and promethazine, commonly termed <i>lean</i>/<i>sizzurp</i>, has been identified as a method that some individuals use to cope with PTSD and other mental health symptomology. A sample of 1423 adults with self-reported past year lean use was recruited from substance-related Reddit pages to complete a survey about lean, including information about using lean to cope with emotions, thoughts, or feelings. To be included in the sample, persons needed to: (1) be ⩾18 years old, (2) report past year lean use, (3) complete lean use screeners, and (4) pass data quality checks (eg, bot detection). As Reddit is an online forum, no geographic restrictions were placed on study participation. Data on demographic characteristics, lean use, and mental health disorder symptomology were captured from participants. Logistic regression models included anxiety, depression, and trauma as independent variables along with covariates to examine using lean to cope with emotions, thoughts, or feelings in the past 30 days. Most participants were male (n = 1102; 77.4%), with an average age of 26.9 (SD = 5.2) years. Most participants used included codeine as an ingredient in lean (n = 1060; 74.5%); promethazine was added as an ingredient by 31.7% of the sample (n = 451), and the combination of codeine and promethazine was included as ingredients by 13.5% (n = 192) of the sample. Participants with anxiety, lifetime trauma exposure, and who were female had increased odds of using lean to cope with emotions, thoughts, or feelings in the past 30 days. Those with depression and unstable housing exhibited decreased odds of using lean to cope with emotions, thoughts, or feelings in the past 30 days. This study recruited persons via social media to learn more about lean use, especially lean use to cope with mental health symptoms; future population-level studies are needed.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231195226"},"PeriodicalIF":2.1,"publicationDate":"2023-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/f0/10.1177_11782218231195226.PMC10517614.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41137533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-09-15eCollection Date: 2023-01-01DOI: 10.1177/11782218231199372
Sarah E Zemore, Kelly L Ziemer, Paul A Gilbert, Mitchell P Karno, Lee Ann Kaskutas
Background: Substance use disorder (SUD) resolution typically involves a long-term, comprehensive process of change now widely referred to as "recovery." Yet, definitions of recovery vary substantially, producing significant confusion. To support formal recovery definitions, we aimed to systematically identify recovery elements that are central to those in recovery and shared regardless of subgroup/pathway.
Methods: Data were from the What is Recovery? Study, involving a diverse, national, online survey of people in recovery (N = 9341). Surveys included a 35-item recovery measure reflecting 4 domains; participants reported whether or not each element definitely belonged in their recovery definitions. Analyses examined item endorsements overall and among 30 subgroups defined a priori (by sociodemographics, substance use characteristics, and help-seeking history) to determine where items met study-specific centrality thresholds (ie, endorsement by ⩾80% and top-10 ranking, by endorsement level). We then classified items as "core" if meeting centrality thresholds both overall and for all 30 subgroups, and "prevalent" if meeting centrality thresholds overall and for 26 to 29 subgroups.
Results: Four "core" recovery elements emerged, including a process of growth or development; being honest with oneself; taking responsibility for the things one can change; and reacting in a more balanced way. Four "prevalent" recovery elements also emerged, referencing the ability to enjoy life and handle negative feelings without substance use; abstinence and/or nonproblematic substance use; and living a life that contributes. Subgroups differing most in their endorsements included those reporting mild/moderate SUD severity; non-abstinent recovery; and no specialty treatment or mutual-help group attendance.
Conclusions: Recovery elements identified here partially reflect some stakeholder definitions, but offer greater specificity and include novel elements (eg, personal integrity). Elements may point to areas of functioning that are damaged in the addiction process and can support an addiction-free life. Findings should inform institutional recovery definitions; SUD services and research; and communications about recovery.
背景:药物使用障碍(SUD)的解决通常涉及一个长期、全面的变化过程,现在被广泛称为“恢复”。然而,恢复的定义差异很大,造成了严重的混乱。为了支持正式的恢复定义,我们旨在系统地识别恢复元素,这些恢复元素是恢复中的核心,并且无论子组/路径如何都是共享的。方法:数据来自What is recovery?这项研究涉及一项针对康复人群的全国性在线调查(N = 9341)。调查包括反映4个领域的35项恢复措施;参与者报告了每个元素是否明确属于他们的恢复定义。分析对项目背书进行了总体检查,并在先验定义的30个亚组中(通过社会人口统计学、物质使用特征和求助史)确定项目在哪些方面符合研究特定的中心性阈值(即,80%的背书和前10名的背书水平)。然后,如果总体上和所有30个亚组都达到中心性阈值,我们将项目分类为“核心”,如果整体上和26至29个亚组达到中心性门限,我们将其分类为“普遍”。结果:出现了四个“核心”恢复要素,包括成长或发展过程;对自己诚实;对自己可以改变的事情负责;并以更平衡的方式进行反应。还出现了四个“普遍”的恢复要素,即在不使用物质的情况下享受生活和处理负面情绪的能力;禁欲和/或非问题药物使用;过着有贡献的生活。背书差异最大的亚组包括报告轻度/中度SUD严重程度的亚组;非禁欲康复;没有特殊治疗或互助小组参与。结论:这里确定的恢复要素部分反映了一些利益相关者的定义,但提供了更大的特异性,并包括新的要素(如个人诚信)。元素可能指向在成瘾过程中受损的功能区域,并可以支持无成瘾生活。调查结果应为机构恢复的定义提供依据;SUD服务和研究;以及关于恢复的通信。
{"title":"Understanding the Shared Meaning of Recovery From Substance Use Disorders: New Findings From the What is Recovery? Study.","authors":"Sarah E Zemore, Kelly L Ziemer, Paul A Gilbert, Mitchell P Karno, Lee Ann Kaskutas","doi":"10.1177/11782218231199372","DOIUrl":"10.1177/11782218231199372","url":null,"abstract":"<p><strong>Background: </strong>Substance use disorder (SUD) resolution typically involves a long-term, comprehensive process of change now widely referred to as \"recovery.\" Yet, definitions of recovery vary substantially, producing significant confusion. To support formal recovery definitions, we aimed to systematically identify recovery elements that are central to those in recovery and shared regardless of subgroup/pathway.</p><p><strong>Methods: </strong>Data were from the What is Recovery? Study, involving a diverse, national, online survey of people in recovery (N = 9341). Surveys included a 35-item recovery measure reflecting 4 domains; participants reported whether or not each element definitely belonged in their recovery definitions. Analyses examined item endorsements overall and among 30 subgroups defined <i>a priori</i> (by sociodemographics, substance use characteristics, and help-seeking history) to determine where items met study-specific centrality thresholds (ie, endorsement by ⩾80% and top-10 ranking, by endorsement level). We then classified items as \"core\" if meeting centrality thresholds both overall and for all 30 subgroups, and \"prevalent\" if meeting centrality thresholds overall and for 26 to 29 subgroups.</p><p><strong>Results: </strong>Four \"core\" recovery elements emerged, including a process of growth or development; being honest with oneself; taking responsibility for the things one can change; and reacting in a more balanced way. Four \"prevalent\" recovery elements also emerged, referencing the ability to enjoy life and handle negative feelings without substance use; abstinence and/or nonproblematic substance use; and living a life that contributes. Subgroups differing most in their endorsements included those reporting mild/moderate SUD severity; non-abstinent recovery; and no specialty treatment or mutual-help group attendance.</p><p><strong>Conclusions: </strong>Recovery elements identified here partially reflect some stakeholder definitions, but offer greater specificity and include novel elements (eg, personal integrity). Elements may point to areas of functioning that are damaged in the addiction process and can support an addiction-free life. Findings should inform institutional recovery definitions; SUD services and research; and communications about recovery.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231199372"},"PeriodicalIF":2.0,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f4/91/10.1177_11782218231199372.PMC10508054.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41130143","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-07-18eCollection Date: 2023-01-01DOI: 10.1177/11782218231186371
Aviva K Olsavsky, Isabella Chirico, Diab Ali, Hannah Christensen, Brianna Boggs, Lillian Svete, Katherine Ketcham, Kent Hutchison, Charles Zeanah, Nim Tottenham, Paula Riggs, C Neill Epperson
The parent-infant relationship is critical for socioemotional development and is adversely impacted by perinatal substance use. This systematic review posits that the mechanisms underlying these risks to mother-infant relationships center on 3 primary processes: (1) mothers' childhood maltreatment experiences; (2) attachment styles and consequent internal working models of interpersonal relationships; and (3) perinatal substance use. Further, the review considers the role of hyperkatifeia, or hypersensitivity to negative affect which occurs when people with substance use disorders are not using substances, and which drives the negative reinforcement in addiction. The authors performed a systematic review of articles (published 2000-2022) related to these constructs and their impact on mother-infant relationships and offspring outcomes, including original clinical research articles addressing relationships between these constructs, and excluding case studies, reviews, non-human animal studies, intervention studies, studies with fewer than 30% female-sex participants, clinical guidelines, studies limited to obstetric outcomes, mechanistic/biological studies, and studies with methodological issues precluding interpretation. Overall 1844 articles were screened, 377 were selected for full text review, and data were extracted from 157 articles. Results revealed strong relationships between mothers' childhood maltreatment experiences, less optimal internal working models, and increased risk for perinatal substance use, and importantly, all of these predictors interacted with hyperkatifeia and exerted a marked impact on mother-infant relationships with less data available on offspring outcomes. These data strongly support the need for future studies addressing the additive impact of maternal childhood maltreatment experiences, suboptimal internal working models, and perinatal substance use, with hyperkatifeia as a potential moderator, and their interacting effects on mother-infant socioemotional outcomes.
{"title":"Maternal Childhood Maltreatment, Internal Working Models, and Perinatal Substance Use: Is There a Role for Hyperkatifeia? A Systematic Review.","authors":"Aviva K Olsavsky, Isabella Chirico, Diab Ali, Hannah Christensen, Brianna Boggs, Lillian Svete, Katherine Ketcham, Kent Hutchison, Charles Zeanah, Nim Tottenham, Paula Riggs, C Neill Epperson","doi":"10.1177/11782218231186371","DOIUrl":"10.1177/11782218231186371","url":null,"abstract":"<p><p>The parent-infant relationship is critical for socioemotional development and is adversely impacted by perinatal substance use. This systematic review posits that the mechanisms underlying these risks to mother-infant relationships center on 3 primary processes: (1) mothers' childhood maltreatment experiences; (2) attachment styles and consequent internal working models of interpersonal relationships; and (3) perinatal substance use. Further, the review considers the role of hyperkatifeia, or hypersensitivity to negative affect which occurs when people with substance use disorders are not using substances, and which drives the negative reinforcement in addiction. The authors performed a systematic review of articles (published 2000-2022) related to these constructs and their impact on mother-infant relationships and offspring outcomes, including original clinical research articles addressing relationships between these constructs, and excluding case studies, reviews, non-human animal studies, intervention studies, studies with fewer than 30% female-sex participants, clinical guidelines, studies limited to obstetric outcomes, mechanistic/biological studies, and studies with methodological issues precluding interpretation. Overall 1844 articles were screened, 377 were selected for full text review, and data were extracted from 157 articles. Results revealed strong relationships between mothers' childhood maltreatment experiences, less optimal internal working models, and increased risk for perinatal substance use, and importantly, all of these predictors interacted with hyperkatifeia and exerted a marked impact on mother-infant relationships with less data available on offspring outcomes. These data strongly support the need for future studies addressing the additive impact of maternal childhood maltreatment experiences, suboptimal internal working models, and perinatal substance use, with hyperkatifeia as a potential moderator, and their interacting effects on mother-infant socioemotional outcomes.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231186371"},"PeriodicalIF":2.1,"publicationDate":"2023-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d4/3b/10.1177_11782218231186371.PMC10354827.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10665728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-06eCollection Date: 2023-01-01DOI: 10.1177/11782218231179039
Matthew G Lemansky, Anna K Martin, Judith A Bernstein, Sabrina A Assoumou
Policy changes resulting from the coronavirus 2019 (COVID-19) pandemic have had a substantial and positive impact on the clinical care of persons with opioid use disorder. These innovative paradigm shifts created a ripe environment for re-evaluating traditional approaches to recruiting and retaining persons who use drugs into research studies. For example, changes to methadone prescribing requirements and authorization of buprenorphine prescriptions via telehealth have both increased access to medications. In this commentary, we contribute to ongoing conversations about the ethics of compensation for participants in addiction-related clinical research and share methods of payment that proved successful in research performed during the pandemic. We also discuss approaches to enrollment and follow-up that were implemented during the height of COVID restrictions. These approaches may mutually benefit both participants and researchers in a post-pandemic era.
{"title":"Research Compensation and Enhanced Contacts in Studies With Persons Who Use Drugs: Lessons From the COVID-19 Pandemic Demand a Reset.","authors":"Matthew G Lemansky, Anna K Martin, Judith A Bernstein, Sabrina A Assoumou","doi":"10.1177/11782218231179039","DOIUrl":"10.1177/11782218231179039","url":null,"abstract":"<p><p>Policy changes resulting from the coronavirus 2019 (COVID-19) pandemic have had a substantial and positive impact on the clinical care of persons with opioid use disorder. These innovative paradigm shifts created a ripe environment for re-evaluating traditional approaches to recruiting and retaining persons who use drugs into research studies. For example, changes to methadone prescribing requirements and authorization of buprenorphine prescriptions via telehealth have both increased access to medications. In this commentary, we contribute to ongoing conversations about the ethics of compensation for participants in addiction-related clinical research and share methods of payment that proved successful in research performed during the pandemic. We also discuss approaches to enrollment and follow-up that were implemented during the height of COVID restrictions. These approaches may mutually benefit both participants and researchers in a post-pandemic era.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231179039"},"PeriodicalIF":2.0,"publicationDate":"2023-06-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/1c/10.1177_11782218231179039.PMC10251077.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10351427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-07eCollection Date: 2023-01-01DOI: 10.1177/11782218231166622
Timothy J Grigsby, Andrea Lopez, Larisa Albers, Christopher J Rogers, Myriam Forster
Objective: Numerous reviews have examined risk and protective factors for alcohol-related negative consequences, but no equivalent review of risk and protective factors exists for cannabis-related negative consequences (CRNCs)-a gap filled by the present study. This scoping review examined survey-based research of risk and protective factors for CRNCs such as neglecting responsibilities, blacking out, or needing more cannabis.
Methods: Three databases (PubMed, PsycINFO, and Google Scholar) were searched for peer-reviewed manuscripts published between January 1, 1990, and December 31, 2021. A qualitative synthesis was performed using the matrix method and the results were organized using the socioecological model as a framework.
Results: Eighty-three studies were included in the review. There was considerable variation in measures and operationalizations of CRNCs across studies. Risk factors were identified in the intrapersonal (depression, social anxiety, PTSD, impulsivity, sensation seeking, motives, expectancies), interpersonal/community (trauma, victimization, family and peer substance use, social norms), and social/policy (education, employment, community attachment, legalization, availability of substances) domains of influence. Protective behavioral strategies were a robust protective factor for CRNCs. Males consistently reported more CRNCs than females, but there were no differences observed across race.
Conclusions: Future research should identify person- and product-specific patterns of CRNCs to refine theoretical models of cannabis misuse and addiction. Public health interventions to reduce the risk of negative consequences from cannabis should consider utilizing multilevel interventions to attenuate the cumulative risk from a combination of psychological, contextual, and social influences.
{"title":"A Scoping Review of Risk and Protective Factors for Negative Cannabis Use Consequences.","authors":"Timothy J Grigsby, Andrea Lopez, Larisa Albers, Christopher J Rogers, Myriam Forster","doi":"10.1177/11782218231166622","DOIUrl":"10.1177/11782218231166622","url":null,"abstract":"<p><strong>Objective: </strong>Numerous reviews have examined risk and protective factors for alcohol-related negative consequences, but no equivalent review of risk and protective factors exists for cannabis-related negative consequences (CRNCs)-a gap filled by the present study. This scoping review examined survey-based research of risk and protective factors for CRNCs such as neglecting responsibilities, blacking out, or needing more cannabis.</p><p><strong>Methods: </strong>Three databases (PubMed, PsycINFO, and Google Scholar) were searched for peer-reviewed manuscripts published between January 1, 1990, and December 31, 2021. A qualitative synthesis was performed using the matrix method and the results were organized using the socioecological model as a framework.</p><p><strong>Results: </strong>Eighty-three studies were included in the review. There was considerable variation in measures and operationalizations of CRNCs across studies. Risk factors were identified in the <i>intrapersonal</i> (depression, social anxiety, PTSD, impulsivity, sensation seeking, motives, expectancies), <i>interpersonal/community</i> (trauma, victimization, family and peer substance use, social norms), and <i>social/policy</i> (education, employment, community attachment, legalization, availability of substances) domains of influence. Protective behavioral strategies were a robust protective factor for CRNCs. Males consistently reported more CRNCs than females, but there were no differences observed across race.</p><p><strong>Conclusions: </strong>Future research should identify person- and product-specific patterns of CRNCs to refine theoretical models of cannabis misuse and addiction. Public health interventions to reduce the risk of negative consequences from cannabis should consider utilizing multilevel interventions to attenuate the cumulative risk from a combination of psychological, contextual, and social influences.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231166622"},"PeriodicalIF":2.0,"publicationDate":"2023-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/6b/4e/10.1177_11782218231166622.PMC10087658.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9304996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-04-06eCollection Date: 2023-01-01DOI: 10.1177/11782218231166382
Sandra Oreper, Allison Bond, Marilyn Bazinski, Matthew Tierney, Margaret Fang, Sujatha Sankaran, Aksharananda Rambachan
Background: Patients experiencing homelessness have higher rates of substance use and related mortality, often driven by opioid overdose. Conversely, opioid use disorder (OUD) is a leading risk factor for homelessness. Our goal was to test the efficacy of an electronic health record (EHR) screen in identifying this vulnerable population during hospitalization and to assess the feasibility of a bundled intervention in improving opioid safety.
Methods: We assessed patients' housing status, substance use, previous MOUD treatment, barriers to MOUD treatment and readiness to take MOUD in and out of the hospital. For each post discharge follow up call, patients were asked about their MOUD status, barriers accessing treatment, current substance use, and housing status. We also assessed team members perceptions and experiences of the study.
Results: We enrolled 32 patients with housing insecurity and OUD. The mean age was 44, the majority self-identified as male (78%), and mostly as White (56%) or Black (38%). At each follow up within the 6-months post-discharge, reach rates were low: 40% of enrollees answered at least 1 call and the highest reach rate (31% of patients) occurred at week 4. At the third and sixth-month follow ups, >50% of subjects still taking MOUD were also using opioids.
Conclusion: Our clinician augmented EHR screen accurately identified inpatients experiencing OUD and PEH. This intervention showed high rates of attrition among enrolled patients, even after providing cellphones. The majority of patients who were reached remained adherent to MOUD though they reported significant barriers.
{"title":"A Focused Screening and Clinical Intervention with Streamlined Outpatient Linkage for Hospitalized Patients with Opioid Use Disorder Experiencing Homelessness.","authors":"Sandra Oreper, Allison Bond, Marilyn Bazinski, Matthew Tierney, Margaret Fang, Sujatha Sankaran, Aksharananda Rambachan","doi":"10.1177/11782218231166382","DOIUrl":"10.1177/11782218231166382","url":null,"abstract":"<p><strong>Background: </strong>Patients experiencing homelessness have higher rates of substance use and related mortality, often driven by opioid overdose. Conversely, opioid use disorder (OUD) is a leading risk factor for homelessness. Our goal was to test the efficacy of an electronic health record (EHR) screen in identifying this vulnerable population during hospitalization and to assess the feasibility of a bundled intervention in improving opioid safety.</p><p><strong>Methods: </strong>We assessed patients' housing status, substance use, previous MOUD treatment, barriers to MOUD treatment and readiness to take MOUD in and out of the hospital. For each post discharge follow up call, patients were asked about their MOUD status, barriers accessing treatment, current substance use, and housing status. We also assessed team members perceptions and experiences of the study.</p><p><strong>Results: </strong>We enrolled 32 patients with housing insecurity and OUD. The mean age was 44, the majority self-identified as male (78%), and mostly as White (56%) or Black (38%). At each follow up within the 6-months post-discharge, reach rates were low: 40% of enrollees answered at least 1 call and the highest reach rate (31% of patients) occurred at week 4. At the third and sixth-month follow ups, >50% of subjects still taking MOUD were also using opioids.</p><p><strong>Conclusion: </strong>Our clinician augmented EHR screen accurately identified inpatients experiencing OUD and PEH. This intervention showed high rates of attrition among enrolled patients, even after providing cellphones. The majority of patients who were reached remained adherent to MOUD though they reported significant barriers.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231166382"},"PeriodicalIF":2.0,"publicationDate":"2023-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/5b/f5/10.1177_11782218231166382.PMC10084569.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9304497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-31eCollection Date: 2023-01-01DOI: 10.1177/11782218231165123
Deirdre Ryan, Marie Naughton, Meabh de Faoite, Tara Dowd, Ann-Marie Morrissey
Introduction: Substance use disorders (SUDs) and addictive behaviours are growing problems which negatively impact health and wellbeing. Occupational therapy can support recovery by facilitating engagement in everyday activities that promote health. To date, the inclusion of occupational therapy in addiction recovery is limited and the evidence base for occupation-focused interventions is lacking. This study explores the impact of an occupational therapy-led intervention on self-reported occupational performance and occupational balance issues for people living with SUDs within an inpatient addiction service.
Methodology: A quantitative pre and post-test study was implemented. The Canadian Personal Recovery Outcome Measure (C-PROM) was the sole outcome measure. The C-PROM is a self-report measure which aims to measure personal views of recovery based on rating activity engagement. The cohort of participants were recruited from referrals into 2 inpatient addiction recovery treatment programmes using purposive sampling. Descriptive statistics were run, and a Wilcoxon Signed Rank Test was used to analyse pre and post-test scoring.
Results: Sixteen participants (9 male and 7 female) completed the intervention and outcome measure. The majority of participants (31.3%, n = 5) were between 45 and 54 years old. 25% of the sample (n = 4) were in the 35 to 44 age bracket while 18.8% (n = 3) were aged 55 to 64. The majority of participants (68.8%, n = 11) reported substance misuse as their main healthcare concern. The mean score on the C-PROM was significantly higher after participants received the intervention when compared with baseline scoring.
Conclusion: Following engagement with an occupational therapist-led intervention participants reported increased engagement in activities and occupational performance. Participants also reported improved occupational balance and increased awareness of personal recovery needs. Further research is required to explore the effectiveness of this intervention in larger samples and to explore the transferability and sustainability of skills post discharge.
{"title":"An Occupation-Based Lifestyle Lecture Intervention as Part of Inpatient Addiction Recovery Treatment: Exploring Occupational Performance, Balance and Personal Recovery.","authors":"Deirdre Ryan, Marie Naughton, Meabh de Faoite, Tara Dowd, Ann-Marie Morrissey","doi":"10.1177/11782218231165123","DOIUrl":"10.1177/11782218231165123","url":null,"abstract":"<p><strong>Introduction: </strong>Substance use disorders (SUDs) and addictive behaviours are growing problems which negatively impact health and wellbeing. Occupational therapy can support recovery by facilitating engagement in everyday activities that promote health. To date, the inclusion of occupational therapy in addiction recovery is limited and the evidence base for occupation-focused interventions is lacking. This study explores the impact of an occupational therapy-led intervention on self-reported occupational performance and occupational balance issues for people living with SUDs within an inpatient addiction service.</p><p><strong>Methodology: </strong>A quantitative pre and post-test study was implemented. The Canadian Personal Recovery Outcome Measure (C-PROM) was the sole outcome measure. The C-PROM is a self-report measure which aims to measure personal views of recovery based on rating activity engagement. The cohort of participants were recruited from referrals into 2 inpatient addiction recovery treatment programmes using purposive sampling. Descriptive statistics were run, and a Wilcoxon Signed Rank Test was used to analyse pre and post-test scoring.</p><p><strong>Results: </strong>Sixteen participants (9 male and 7 female) completed the intervention and outcome measure. The majority of participants (31.3%, n = 5) were between 45 and 54 years old. 25% of the sample (n = 4) were in the 35 to 44 age bracket while 18.8% (n = 3) were aged 55 to 64. The majority of participants (68.8%, n = 11) reported substance misuse as their main healthcare concern. The mean score on the C-PROM was significantly higher after participants received the intervention when compared with baseline scoring.</p><p><strong>Conclusion: </strong>Following engagement with an occupational therapist-led intervention participants reported increased engagement in activities and occupational performance. Participants also reported improved occupational balance and increased awareness of personal recovery needs. Further research is required to explore the effectiveness of this intervention in larger samples and to explore the transferability and sustainability of skills post discharge.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231165123"},"PeriodicalIF":2.0,"publicationDate":"2023-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/5a/10.1177_11782218231165123.PMC10068992.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9257806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-22eCollection Date: 2023-01-01DOI: 10.1177/11782218231160014
Angela McLaughlin, Rebecca Burns, Morgan Ryan, Wafaa Abbasi, Leah Harvey, Jacqueline Hicks, Pranay Sinha, Sabrina A Assoumou
Objectives: People with substance use disorders (SUD) are suggested to have higher risk of hospitalization, intubation, or death from coronavirus disease 2019 (COVID-19), although data are mixed. Little is known about other COVID-19-related complications in this group. We compared morbidity and mortality among individuals with and without SUD who were admitted to an urban safety net hospital with COVID-19 early in the pandemic, contemporaneous to other published studies on this subject.
Methods: We performed a retrospective study of patients ⩾18 years old admitted with COVID-19 from March 16th to April 8th, 2020. SUD included alcohol, opioid, cocaine, amphetamine, and benzodiazepine use disorders and was identified using diagnostic codes, free text clinical documentation, and urine drug screens. The primary outcome was inpatient mortality. Secondary outcomes included clinical complications (eg, secondary infections, venous thromboembolism) and resource utilization (eg, mechanical ventilation, length of stay). We used multivariable regression to assess the relationship between SUD and mortality.
Results: Of 409 patients, the mean age was 56 years and 13.7% had SUD. Those with SUD were more likely to be male, have experienced homelessness, have pulmonary disease or hepatitis C, or use tobacco or cannabis. After multivariable analysis, SUD was not associated with mortality (aOR 1.03; 95% CI, 0.31-3.10). Secondary outcomes were also similar between groups.
Conclusions: Our findings suggest that persons with and without SUD have similar COVID-19-related outcomes. Previously reported increased COVID-19 complications may be from medical comorbidities.
目的:有研究表明,有药物使用障碍(SUD)的人因冠状病毒病 2019(COVID-19)住院、插管或死亡的风险较高,但数据不一。人们对这一群体中与 COVID-19 相关的其他并发症知之甚少。我们比较了在大流行早期因 COVID-19 而入住城市安全网医院的 SUD 患者和非 SUD 患者的发病率和死亡率,这与其他已发表的相关研究结果是同步的:我们对 2020 年 3 月 16 日至 4 月 8 日期间因 COVID-19 入院的 18 岁以下患者进行了回顾性研究。SUD 包括酒精、阿片类药物、可卡因、苯丙胺和苯二氮卓类药物使用障碍,并通过诊断代码、自由文本临床文件和尿液药物筛查进行识别。主要结果为住院病人死亡率。次要结果包括临床并发症(如继发感染、静脉血栓栓塞)和资源利用率(如机械通气、住院时间)。我们采用多变量回归法评估 SUD 与死亡率之间的关系:在 409 名患者中,平均年龄为 56 岁,13.7% 患有 SUD。有 SUD 的患者更有可能是男性、无家可归者、患有肺部疾病或丙型肝炎、吸烟或吸食大麻。经过多变量分析,SUD 与死亡率无关(aOR 1.03;95% CI,0.31-3.10)。各组之间的次要结果也相似:我们的研究结果表明,有 SUD 和没有 SUD 的人群具有相似的 COVID-19 相关结果。之前报道的 COVID-19 并发症增加可能是由于合并症引起的。
{"title":"Comparing COVID-19-related Morbidity and Mortality Between Patients With and Without Substance Use Disorders: A Retrospective Cohort Study.","authors":"Angela McLaughlin, Rebecca Burns, Morgan Ryan, Wafaa Abbasi, Leah Harvey, Jacqueline Hicks, Pranay Sinha, Sabrina A Assoumou","doi":"10.1177/11782218231160014","DOIUrl":"10.1177/11782218231160014","url":null,"abstract":"<p><strong>Objectives: </strong>People with substance use disorders (SUD) are suggested to have higher risk of hospitalization, intubation, or death from coronavirus disease 2019 (COVID-19), although data are mixed. Little is known about other COVID-19-related complications in this group. We compared morbidity and mortality among individuals with and without SUD who were admitted to an urban safety net hospital with COVID-19 early in the pandemic, contemporaneous to other published studies on this subject.</p><p><strong>Methods: </strong>We performed a retrospective study of patients ⩾18 years old admitted with COVID-19 from March 16th to April 8th, 2020. SUD included alcohol, opioid, cocaine, amphetamine, and benzodiazepine use disorders and was identified using diagnostic codes, free text clinical documentation, and urine drug screens. The primary outcome was inpatient mortality. Secondary outcomes included clinical complications (eg, secondary infections, venous thromboembolism) and resource utilization (eg, mechanical ventilation, length of stay). We used multivariable regression to assess the relationship between SUD and mortality.</p><p><strong>Results: </strong>Of 409 patients, the mean age was 56 years and 13.7% had SUD. Those with SUD were more likely to be male, have experienced homelessness, have pulmonary disease or hepatitis C, or use tobacco or cannabis. After multivariable analysis, SUD was not associated with mortality (aOR 1.03; 95% CI, 0.31-3.10). Secondary outcomes were also similar between groups.</p><p><strong>Conclusions: </strong>Our findings suggest that persons with and without SUD have similar COVID-19-related outcomes. Previously reported increased COVID-19 complications may be from medical comorbidities.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231160014"},"PeriodicalIF":2.0,"publicationDate":"2023-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1c/77/10.1177_11782218231160014.PMC10034287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9560577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-13eCollection Date: 2023-01-01DOI: 10.1177/11782218231153748
Hiroko Furo, Timothy Wiegand, Meenakshi Rani, Diane G Schwartz, Ross W Sullivan, Peter L Elkin
<p><strong>Background: </strong>Utilizing a 1-year chart review as the data, Furo et al. conducted a research study on an association between buprenorphine dose and the urine "norbuprenorphine" to "creatinine" ratio and found significant differences in the ratio among 8-, 12-, and 16-mg/day groups with an analysis of variance (ANOVA) test. This study expands the data for a 2-year chart review and is intended to delineate an association between buprenorphine dose and the urine "norbuprenorphine" to "creatinine" ratio with a higher statistical power.</p><p><strong>Methods: </strong>This study performed a 2-year chart review of data for the patients living in a halfway house setting, where their drug administration was closely monitored. The patients were on buprenorphine prescribed at an outpatient clinic for opioid use disorder (OUD), and their buprenorphine prescription and dispensing information were confirmed by the New York Prescription Drug Monitoring Program (PDMP). Urine test results in the electronic health record (EHR) were reviewed, focusing on the "buprenorphine," "norbuprenorphine," and "creatinine" levels. The Kruskal-Wallis <i>H</i> and Mann-Whitney <i>U</i> tests were performed to examine an association between buprenorphine dose and the "norbuprenorphine" to "creatinine" ratio.</p><p><strong>Results: </strong>This study included 371 urine samples from 61 consecutive patients and analyzed the data in a manner similar to that described in the study by Furo et al. This study had similar findings with the following exceptions: (1) a mean buprenorphine dose of 11.0 ± 3.8 mg/day with a range of 2 to 20 mg/day; (2) exclusion of 6 urine samples with "creatinine" level <20 mg/dL; (3) minimum "norbuprenorphine" to "creatinine" ratios in the 8-, 12-, and 16-mg/day groups of 0.44 × 10<sup>-4</sup> (n = 68), 0.1 × 10<sup>-4</sup> (n = 133), and 1.37 × 10<sup>-4</sup> (n = 82), respectively; however, after removing the 2 lowest outliers, the minimum "norbuprenorphine" to "creatinine" ratio in the 12-mg/day group was 1.6 × 10<sup>-4</sup>, similar to the findings in the previous study; and (4) a significant association between buprenorphine dose and the urine "norbuprenorphine" to "creatinine" ratios from the Kruskal-Wallis test (<i>P</i> < .01). In addition, the median "norbuprenorphine" to "creatinine" ratio had a strong association with buprenorphine dose, and this association could be formulated as: [y = 2.266 ln(<i>x</i>) + 0.8211]. In other words, the median ratios in 8-, 12-, and 16-mg/day groups were 5.53 × 10<sup>-4</sup>, 6.45 × 10<sup>-4</sup>, and 7.10 × 10<sup>-4</sup>, respectively. Therefore, any of the following features should alert providers to further investigate patient treatment compliance: (1) inappropriate substance(s) in urine sample; (2) "creatinine" level <20 mg/dL; (3) "buprenorphine" to "norbuprenorphine" ratio >50:1; (4) buprenorphine dose >24 mg/day; or (5) "norbuprenorphine" to "creatinine" ratios <0.5 × 10<sup>-4</
{"title":"Association Between Buprenorphine Dose and the Urine \"Norbuprenorphine\" to \"Creatinine\" Ratio: Revised.","authors":"Hiroko Furo, Timothy Wiegand, Meenakshi Rani, Diane G Schwartz, Ross W Sullivan, Peter L Elkin","doi":"10.1177/11782218231153748","DOIUrl":"10.1177/11782218231153748","url":null,"abstract":"<p><strong>Background: </strong>Utilizing a 1-year chart review as the data, Furo et al. conducted a research study on an association between buprenorphine dose and the urine \"norbuprenorphine\" to \"creatinine\" ratio and found significant differences in the ratio among 8-, 12-, and 16-mg/day groups with an analysis of variance (ANOVA) test. This study expands the data for a 2-year chart review and is intended to delineate an association between buprenorphine dose and the urine \"norbuprenorphine\" to \"creatinine\" ratio with a higher statistical power.</p><p><strong>Methods: </strong>This study performed a 2-year chart review of data for the patients living in a halfway house setting, where their drug administration was closely monitored. The patients were on buprenorphine prescribed at an outpatient clinic for opioid use disorder (OUD), and their buprenorphine prescription and dispensing information were confirmed by the New York Prescription Drug Monitoring Program (PDMP). Urine test results in the electronic health record (EHR) were reviewed, focusing on the \"buprenorphine,\" \"norbuprenorphine,\" and \"creatinine\" levels. The Kruskal-Wallis <i>H</i> and Mann-Whitney <i>U</i> tests were performed to examine an association between buprenorphine dose and the \"norbuprenorphine\" to \"creatinine\" ratio.</p><p><strong>Results: </strong>This study included 371 urine samples from 61 consecutive patients and analyzed the data in a manner similar to that described in the study by Furo et al. This study had similar findings with the following exceptions: (1) a mean buprenorphine dose of 11.0 ± 3.8 mg/day with a range of 2 to 20 mg/day; (2) exclusion of 6 urine samples with \"creatinine\" level <20 mg/dL; (3) minimum \"norbuprenorphine\" to \"creatinine\" ratios in the 8-, 12-, and 16-mg/day groups of 0.44 × 10<sup>-4</sup> (n = 68), 0.1 × 10<sup>-4</sup> (n = 133), and 1.37 × 10<sup>-4</sup> (n = 82), respectively; however, after removing the 2 lowest outliers, the minimum \"norbuprenorphine\" to \"creatinine\" ratio in the 12-mg/day group was 1.6 × 10<sup>-4</sup>, similar to the findings in the previous study; and (4) a significant association between buprenorphine dose and the urine \"norbuprenorphine\" to \"creatinine\" ratios from the Kruskal-Wallis test (<i>P</i> < .01). In addition, the median \"norbuprenorphine\" to \"creatinine\" ratio had a strong association with buprenorphine dose, and this association could be formulated as: [y = 2.266 ln(<i>x</i>) + 0.8211]. In other words, the median ratios in 8-, 12-, and 16-mg/day groups were 5.53 × 10<sup>-4</sup>, 6.45 × 10<sup>-4</sup>, and 7.10 × 10<sup>-4</sup>, respectively. Therefore, any of the following features should alert providers to further investigate patient treatment compliance: (1) inappropriate substance(s) in urine sample; (2) \"creatinine\" level <20 mg/dL; (3) \"buprenorphine\" to \"norbuprenorphine\" ratio >50:1; (4) buprenorphine dose >24 mg/day; or (5) \"norbuprenorphine\" to \"creatinine\" ratios <0.5 × 10<sup>-4</","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231153748"},"PeriodicalIF":2.1,"publicationDate":"2023-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0b/88/10.1177_11782218231153748.PMC10014968.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9499456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-02-27eCollection Date: 2023-01-01DOI: 10.1177/11782218231152818
Anthony A Olashore, Saeeda Paruk, Merrian Brooks, Bonginkosi Chiliza
Substance use is a major obstacle to preventing and managing HIV among adolescents, who account for 30% of new infections in many parts of the world, including Botswana. Unfortunately, there is a paucity of data on adolescent substance use, especially in the region. Therefore, this study aimed to determine the pattern of psychoactive substance use in adolescents living with HIV (ALWHIV). It also aimed to compare and explore the pattern of substance use disorders and associated factors between congenitally infected adolescents (CIAs) and behaviorally infected adolescents (BIAs). Six hundred and thirty-four ALWHIV were interviewed using a sociodemographic questionnaire, the WHO drug questionnaire, and DSM-5 criteria for substance use disorder. The participants' mean age (SD) was 17.69 (1.6) years, with a male predominance (n = 336, 53%), and the majority (n = 411, 64.8%) were CIAs. Alcohol was the most used substance among the participants, with 15.8% admitting to its current use. The BIAs were more likely to have SUD (χ2 = 17.2, P < .01), use more than one substance (χ2 = 20.3, P < .01), and more likely to use all psychoactive substances except for inhalants. In the CIAs, regular participation in religious activities was negatively associated with SUD (AOR = 0.36; 95% CI: 0.17-0.77), while struggling with HIV status acceptance was positively associated with SUD (AOR = 2.54; 95% CI: 1.15-5.61) in the BIAs. This study showed a huge burden and similar pattern of substance use disorders among the ALWHIV in Botswana, as reported elsewhere. It also identified the dissimilarities between the BIAs and CIAs regarding substance-related issues and suggested the need for differentiated care.
{"title":"Psychoactive Substance Use Disorder in HIV-Infected Adolescents in Botswana: A Comparison Between the Congenitally Infected and Behaviorally Infected Adolescents.","authors":"Anthony A Olashore, Saeeda Paruk, Merrian Brooks, Bonginkosi Chiliza","doi":"10.1177/11782218231152818","DOIUrl":"10.1177/11782218231152818","url":null,"abstract":"<p><p>Substance use is a major obstacle to preventing and managing HIV among adolescents, who account for 30% of new infections in many parts of the world, including Botswana. Unfortunately, there is a paucity of data on adolescent substance use, especially in the region. Therefore, this study aimed to determine the pattern of psychoactive substance use in adolescents living with HIV (ALWHIV). It also aimed to compare and explore the pattern of substance use disorders and associated factors between congenitally infected adolescents (CIAs) and behaviorally infected adolescents (BIAs). Six hundred and thirty-four ALWHIV were interviewed using a sociodemographic questionnaire, the WHO drug questionnaire, and DSM-5 criteria for substance use disorder. The participants' mean age (SD) was 17.69 (1.6) years, with a male predominance (n = 336, 53%), and the majority (n = 411, 64.8%) were CIAs. Alcohol was the most used substance among the participants, with 15.8% admitting to its current use. The BIAs were more likely to have SUD (χ<sup>2</sup> = 17.2, <i>P</i> < .01), use more than one substance (χ<sup>2</sup> = 20.3, <i>P</i> < .01), and more likely to use all psychoactive substances except for inhalants. In the CIAs, regular participation in religious activities was negatively associated with SUD (AOR = 0.36; 95% CI: 0.17-0.77), while struggling with HIV status acceptance was positively associated with SUD (AOR = 2.54; 95% CI: 1.15-5.61) in the BIAs. This study showed a huge burden and similar pattern of substance use disorders among the ALWHIV in Botswana, as reported elsewhere. It also identified the dissimilarities between the BIAs and CIAs regarding substance-related issues and suggested the need for differentiated care.</p>","PeriodicalId":22185,"journal":{"name":"Substance Abuse: Research and Treatment","volume":"17 ","pages":"11782218231152818"},"PeriodicalIF":2.0,"publicationDate":"2023-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/4a/10.1177_11782218231152818.PMC9974603.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9395929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}